Podcasts about personalised treatment

Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota, USA.     Timestamps  01:44 – Quickfire questions  07:25 – CAR-T cell therapy  10:48 – Anti-CD38 antibodies  13:31 – Minimal residual disease  14:30 – Bispecific antibodies  15:31 – Antibody-drug conjugates  19:04 – ASCO 2025  21:24 – Genetic discoveries  26:28 – Fonseca's three wishes 

Send us a textCould you be living with OCD without realizing it? How can naturopathic treatments like hormone regulation and gut health support aid in recovery?

Computational power, AI, genomics: the treatment and diagnosis of prostate cancer is advancing rapidly. This episode finds out how.  A leap forward in the diagnosis and treatment would be very welcome: prostate cancer is the second most frequent malignancy in men. In 2020 alone, around one and a half million new cases and almost half a million deaths were registered worldwide.  To explore new diagnostics and treatment are:  Jan Tkac, founder and chief scientific officer at Glycanostics, in Slovakia. The company has developed an innovative diagnostic test for cancer, based on novel biomarkers. Jan is also keen to explore how different sports relate to the levels of endorphin release.  Harald Mischak, chief scientific officer of Mosaiques Diagnostics & Therapeutics, Germany. Harald is focused on understanding the underlying molecular structures of certain types of cancers.   Joaquin Mateo, group leader of the Prostate Cancer Translational Research Group at Vall d'Hebron Institute of Oncology, in Barcelona. He is especially interested in the development of novel forms of precision medicine. 

IMH trial to study efficacy of personalised transcranial magnetic stimulation for depression. Synopsis: Every first Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. Researchers from the Institute of Mental Health (IMH) and the Yong Loo Lin School of Medicine at the National University of Singapore are studying a new personalised treatment for resistant depression.  It is the personalised version of Transcranial Magnetic Stimulation (TMS), a non-invasive treatment that uses magnetic fields to stimulate and reset the specific part of the brain that regulates mood.  A clinical trial that aims to study its efficacy is currently being conducted at IMH. It pairs TMS with the algorithm of each patient's functional magnetic resonance imaging to identify a precise spot on the head where magnetic stimulation can be applied to achieve better outcomes. In this Health Check podcast episode, ST senior health correspondent Joyce Teo speaks to two experts involved in the trial. Dr Tor Phern Chern is a Senior Consultant at the Mood & Anxiety department and Head of Neurostimulation Service, at IMH and Associate Professor Thomas Yeo is from the Centre for Sleep and Cognition at the Yong Loo Lin School of Medicine. Highlights (click/tap above): 1:28 How does TMS work?  8:47 Using a tape measure to ascertain the target area  10:34 What is depression? 23:29 Using Professor Yeo's algorithm to find an individual treatment target 25:52 What is the trial about?  29:27 Envisioning a future of TMS treatments Produced by: Joyce Teo (joyceteo@sph.com.sg), Ernest Luis, and Eden Soh Edited by: Eden Soh Follow Health Check Podcast here every month and rate us: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ SPH Awedio app: https://www.awedio.sg/ Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read Joyce Teo's stories: https://str.sg/JbxN --- Discover more ST podcast channels: The Usual Place: https://str.sg/5nfm COE Watch: https://str.sg/iTtE In Your Opinion: https://str.sg/w7Qt Asian Insider: https://str.sg/JWa7 Health Check: https://str.sg/JWaN Green Pulse: https://str.sg/JWaf Your Money & Career: https://str.sg/wB2m ST Sports Talk: https://str.sg/JWRE #PopVultures: https://str.sg/JWad Music Lab: https://str.sg/w9TX Discover ST Podcasts: http://str.sg/stpodcasts --- Special edition series: True Crimes Of Asia (6 eps): https://str.sg/i44T The Unsolved Mysteries of South-east Asia (5 eps): https://str.sg/wuZ2 Invisible Asia (9 eps): https://str.sg/wuZn Stop Scams (10 eps): https://str.sg/wuZB Singapore's War On Covid (5 eps): https://str.sg/wuJa --- Follow our shows then, if you like short, practical podcasts! #healthcheckSee omnystudio.com/listener for privacy information.

IMH trial to study efficacy of personalised transcranial magnetic stimulation for depression. Synopsis: Every first Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. Researchers from the Institute of Mental Health (IMH) and the Yong Loo Lin School of Medicine at the National University of Singapore are studying a new personalised treatment for resistant depression.  It is the personalised version of Transcranial Magnetic Stimulation (TMS), a non-invasive treatment that uses magnetic fields to stimulate and reset the specific part of the brain that regulates mood.  A clinical trial that aims to study its efficacy is currently being conducted at IMH. It pairs TMS with the algorithm of each patient's functional magnetic resonance imaging to identify a precise spot on the head where magnetic stimulation can be applied to achieve better outcomes. In this Health Check podcast episode, ST senior health correspondent Joyce Teo speaks to two experts involved in the trial. Dr Tor Phern Chern is a Senior Consultant at the Mood & Anxiety department and Head of Neurostimulation Service, at IMH and Associate Professor Thomas Yeo is from the Centre for Sleep and Cognition at the Yong Loo Lin School of Medicine. Highlights (click/tap above): 1:28 How does TMS work?  8:47 Using a tape measure to ascertain the target area  10:34 What is depression? 23:29 Using Professor Yeo's algorithm to find an individual treatment target 25:52 What is the trial about?  29:27 Envisioning a future of TMS treatments Produced by: Joyce Teo (joyceteo@sph.com.sg), Ernest Luis, and Eden Soh Edited by: Eden Soh Follow Health Check Podcast here every month and rate us: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ SPH Awedio app: https://www.awedio.sg/ Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read Joyce Teo's stories: https://str.sg/JbxN --- Discover more ST podcast channels: The Usual Place: https://str.sg/5nfm COE Watch: https://str.sg/iTtE In Your Opinion: https://str.sg/w7Qt Asian Insider: https://str.sg/JWa7 Health Check: https://str.sg/JWaN Green Pulse: https://str.sg/JWaf Your Money & Career: https://str.sg/wB2m ST Sports Talk: https://str.sg/JWRE #PopVultures: https://str.sg/JWad Music Lab: https://str.sg/w9TX Discover ST Podcasts: http://str.sg/stpodcasts --- Special edition series: True Crimes Of Asia (6 eps): https://str.sg/i44T The Unsolved Mysteries of South-east Asia (5 eps): https://str.sg/wuZ2 Invisible Asia (9 eps): https://str.sg/wuZn Stop Scams (10 eps): https://str.sg/wuZB Singapore's War On Covid (5 eps): https://str.sg/wuJa --- Follow our shows then, if you like short, practical podcasts! #healthcheckSee omnystudio.com/listener for privacy information.

Today I'm talking to internationally recognised eating disorder expert and nutritionist Melainie Rogers, who is founder and CEO of Balance Eating Disorder Treatment Centre in New York City. Melainie is a professor in the Department of Nutrition and Food Studies at New York University. She is a Certified Eating Disorder Registered Dietitian (CEDRD) and Supervisor.  She is the Founder and CEO of Manhattan-based BALANCE Eating Disorder Treatment Center™, now Joint Commission Accredited as a Centre of Excellence with the facility receiving The Gold Seal of Approval® – an internationally recognised symbol of quality and safety in behavioural healthcare. There she leads a team of medical clinicians, therapists, counsellors, nutritionists, dietitians, social workers, coaches all dedicated to whole body and mind recovery for clients of all ages, races and genders seeking to overcome both eating disorders and disordered eating.  Among her many affiliations: founder and past president of the New York City chapter of the International Association of Eating Disorders Professionals Foundation, an Advisory Board Member at the Center for the Study of Anorexia and Bulimia, and a former Board Member of the Binge Eating Disorder Association. Renowned for creating unique treatment and recovery programs derived from a philosophy based on the principles of Intuitive Eating and Health at Every Size, Melainie regularly presents internationally on the latest scientific research and treatment paradigms within the eating disorder recovery community.  BALANCE eating disorder programs utilise an integrative therapeutic approach that incorporates evidence-based treatments into individualised recovery plans that include behavioural therapy, nutrition counselling, group therapy, and meal support to empower clients to develop a sustainable neutral relationship with food, body acceptance and positive self-esteem. In the episode today, Melainie talks about her journey into working in eating disorders, including her own lived experience. She explains the unique approach that BALANCE Eating Disorder Treatment Center offers including a focus around personalised nutrition, Intuitive Eating Principles and Health At Every Size.  She explores vulnerabilities towards eating disorders in the LGBTQ community; exposure therapy around fear foods; healing from binge eating disorder and much more. I hope that you enjoy the conversation..   To find out more about Melainie and Balance Eating Disorder Center: Website: https://balancedtx.com/ Instagram: @balancedtx   This week's sponsor: WeShape https://www.weshape.com/freedom   Harriet Frew's current offers: - Online 10 Steps to Intuitive Eating Course with Harriet Frew - 50% off with code FREEDOMISPOSSIBLE https://www.theeatingdisordertherapist.co.uk/online-courses.html   Eating Disorders Training for Professionals https://www.theeatingdisordertherapist.co.uk/eating-disorders-training-with-harriet-frew.html   Body Image Training for Professionals   https://www.theeatingdisordertherapist.co.uk/body-image-training-with-harriet-frew.html    

In todays episode we interview Lisa Nguyen, a pharmacist and the founder of Astrid Dispensary, to better understand medicinal cannabis. Lisa shares her profound insights into the therapeutic uses of medicinal cannabis, addressing key points such as its applications for chronic pain, mental health, and sleep disorders, as well as the safety profile and potential challenges associated with its use. Key Points: Therapeutic Benefits of Medicinal Cannabis - Medicinal cannabis offers therapeutic benefits for various conditions, including chronic pain, mental health, and sleep disorders. - Many patients turn to medicinal cannabis as a natural alternative to traditional medications. Safety Profile of Medicinal Cannabis - The safety profile of cannabis is relatively good, with studies suggesting it is less addictive than alcohol. - Addictive potential is associated with high doses of THC and prior history of substance abuse. Legal Implications of Driving Under Medicinal Cannabis - Patients prescribed THC-containing products may face legal restrictions when driving, even when not impaired. - Legal limitations can impact patients' daily lives and choices. Advocacy for Legal Changes - Ongoing advocacy efforts aim to change drug law regulations and educate law enforcement about the benefits and responsible use of medicinal cannabis. Medicinal Cannabis as an Option - Medicinal cannabis, despite potential side effects, is considered a valuable option for patients and has a lower risk profile than many traditional medications. Personalised Treatment with Medicinal Cannabis - Medicinal cannabis treatment is tailored to individual patients, taking into account their unique needs. Awareness - Medicinal cannabis is evolving, with growing awareness and increased access for patients in Australia. - Collaboration between medical professionals, advocates, and politicians is driving progress in this field. Medicinal Cannabis for Mental Health - A significant percentage of patients seek medicinal cannabis for mental health conditions, particularly anxiety and stress. - CBD and THC combinations are used to manage anxiety and may help patients reduce high-dose antidepressants. Medicinal Cannabis for Chronic Pain - Chronic pain patients can find relief through medicinal cannabis, which may include conditions like fibromyalgia, endometriosis, and neuropathic pain. Sleep Disorders and Medicinal Cannabis - Insomnia is a common issue, especially among women juggling various responsibilities. - Medicinal cannabis may address sleep problems and improve patients' quality of life Ongoing Advocacy and Education - Advocates work with politicians to change regulations and educate the public about the benefits of medicinal cannabis. This enlightening episode provides valuable insights into the therapeutic uses of medicinal cannabis and addresses key points concerning its safety profile, potential challenges, and ongoing efforts to change regulations, advocating for a more informed and accessible approach to this natural medicine. The Aging Project Podcast delivers weekly interviews to educate, inspire and connect us all. Let's age well, together. WANT TO JOIN THE AGING PROJECT COMMUNITY? If you're ready to get started on making the rest of your life the best of your life, please join our community. www.theagingproject.com.au WANT TO CONNECT ON THE AGING PROJECT SOCIALS? https://www.instagram.com/theagingproject/ https://www.facebook.com/theagingproject WANT TO CONNECT WITH LISA NGUYEN? https://astrid.health/ DID YOU LOVE THIS INTERVIEW? If you found this interview interesting, helpful, entertaining or inspiring, we need your reviews and shares!! Great reviews will enable us to keep creating amazing content to help us all age well – so, if you liked what you heard, we would be so grateful if you took a few seconds to submit a review on iTunes or wherever you get your podcasts. We read every review, and will feature the best ones on our socials! YOU MUST TRY IT! Our sister site, ‘You Must Try It', is here to make shopping for yourself easy again, with a carefully selected range of health, beauty, and lifestyle products. No confusion, no overwhelm – just the good stuff! www.youmusttryit.com https://www.instagram.com/youmusttryit/ GOT FEEDBACK? WE'D LOVE TO HEAR FROM YOU! If you've got feedback or a burning question, please send it to us at hello@theagingproject.com.au CREDITS: Host and Co-founder: Shelley Craft Producer and Co-founder: Amanda Attwood, founder of The Aging Project

Angela George, Consultant Medical Oncologist, Consultant in Oncogenetics, and Clinical Director of Genomics, The Royal Marsden Hospital, London, UK, joins Jonathan to discuss the importance of personalised cancer treatment for patients. George explains her specific interest in germline and somatic mutations in cancer, the hereditary and genetic links in different cancer types, and her focus on genomics research to improve outcomes for patients during and post-treatment.

This presentation centres on Queensland Health's vision to transform the health system by embedding genomics and precision health into routine healthcare delivery. Ides will show how innovative projects intersect and align to the broader agenda and that importantly, the only way we can enable innovation in this complex ecosystem is to support innovation everywhere but making sure the areas and teams are connected. This means that ultimately, system capability is advanced and able to deliver personalised early diagnosis, intervention and treatment, resulting in optimised patient experience and outcomes and reducing low value and harmful care.

“I hope it will happen in our lifetime, that we will start to learn how to use the totality of information that's available on tumours. And I don't just mean genomics, I mean any of it - including all the bits around the tumour, the microenvironment, the immune system. In the last 10 years alone, cancer research has grown phenomenally. It's been extraordinary to be involved in all of it. It's a very real privilege to be to be in this space.”  In this week's episode of The G Word, Chris Wigley is joined by Serena Nik-Zainal, a consultant in clinical genetics, a Cancer Research UK Advanced Clinical Scientist at the University of Cambridge and an Honorary Consultant in Clinical Genetics at Addenbrooke's Hospital in Cambridge. She was the first woman to win the Josef Steiner Cancer Research Award in 2019.  Serena discusses sharing data, personalised treatment for cancer patients and the impact of the 100,000 Genomes Project. She also talks about the involvement of participants, cancer research and the need for genomic data diversity. 

An international collaboration led by researchers from the Children's Cancer Institute and the Kids Cancer Centre at Sydney Children's Hospital is using genetic mapping to tailor treatments to individual children.

Cancer remains one of the world's biggest killers. Lung cancer alone is responsible for 1.7 miliion deaths globally every year, and prevalence in developing markets is very much on the rise. Irrespective of geography, most cases are identified  when they are already at a late stage, and the chances of beating the cancer are much slimmer. Oncimmune's EarlyCDT Lung blood test, first patented nearly 20 years ago, is clinically proven to detect lung cancer on average 4 years before a standard clinical diagnosis. It is a simple, non-invasive finger prick test that has been shown to save lives, as depicted in their moving “Extra Time” campaign on www.extratime.gallery. My guest in this episode is Adam Hill, CEO of Oncimmune, who took the helm in 2018 and led the company into its current strong position, with global partnerships in place and a number of other cancer testing products soon to be announced. This is a relatively rare example of a biotech business with a product that is already saving lives. Adam talks about the significant shift in the oncology community in recent years, to recognise the importance of the immune system in policing cancerous cells. Oncimmune's ImmunoINSIGHTS platform supports pharma companies by working to predict immune related adverse events in patients by profiling autoantibodies and predicting the immune response. They use advanced data science to stratify or triage patients, enhancing drug development and allowing a more personalised and effective treatment. So please listen in to this eye-opening conversation, and contact Oncimmune via the website at www.oncimmune.com - particularly If you are a clinician or a patient wanting to find out more about Oncimmune's Early CDT test, or a pharma company and would like to know more about how Oncimmune's ImmunoINSIGHTS platform can support your drug development.

ecancer visits the Brain Tumour Bank at Southmead Hospital, Bristol, a joint initiative between the NHS and Bristol University. Approximately 7,000 patients in the UK develop primary brain cancer, but there are many more who develop secondary cancer within the brain from different primary sites around the body (such as breast and lung). The brain tumour unit at North Bristol Trust treated over 400 cases of primary brain and spinal cord tumours in 2010. Brain cancer affects both adults and children, and in children it is the second highest cause of death after accidents. One of the major problems with primary brain cancer is that it invades the brain widely as single cells and therefore can be difficult to completely remove by surgery. It also can develop resistance to traditional chemotherapy and therefore tumour relapse is common. Future developments of brain cancer will involve fully understanding each individual’s tumour according to what is driving the abnormal growth of that specific tumour. Then surgery and a range of therapies can be tailored to the individual, providing a personalised medicine approach. Dr Kathreena Kurian, Honorary Consultant Neuropathologist/ University of Bristol Reader in Brain Tumour Research, gives us a background to the tumour bank and Hannah Williams talks us through her PhD research in to a blood test for brain cancer.

Dr Atanasio Pandiella talks to ecancer at the 2012 ESMO meeting in Vienna about the basis of personalised therapies for cancer and what the future holds for this type of treatment. In addition, Dr Paniella talks about the impact that this will have on patients through more efficient treatment with less toxicity and minimising relapse. Technologies that will help in these fields are proteomic and genomic technology that analyse the changes in alterations of the DNA in tumour cells, thus revealing potential targets. The development of these therapies and technologies faces the challenge of costs and efficiency.

Prof Seoane presents at the symposium, 'Translational and tailored, but can we afford it?', at the 22nd European Association for Cancer Research, Barcelona, 8th July 2012. The official EACR-22 sponsored satellite symposium was hosted by ecancer, in partnership with EurocanPlatform and Vall d’Hebron Institute of Oncology.

Dr Katharine Owen talks about the different types of Diabetes in young adults. There are more forms of diabetes than the commonly known type 1 and type 2. Dr Katherine Owen investigates the different characteristics of monogenic diabetes with the aim of creating systematic diagnostics for aetiology of diabetes, and implementing that in clinical care. The ultimate aim is to promote personalized medicine for everybody with diabetes.

Dr Katharine Owen talks about the different types of diabetes in young adults. There are more forms of diabetes than the commonly known type 1 and type 2. Correct diagnosis of the different forms of diabetes is difficult because of the overlap of symptoms. The implications of incorrect diagnosis are huge, as some forms of diabetes respond better to certain treatments than others. Dr Katherine Owen investigates the different characteristics of monogenic diabetes with the aim of creating systematic diagnostics, and implementing that in clinical care. The ultimate aim is to promote personalised medicine for everybody with diabetes.

Dr Katharine Owen talks about the different types of Diabetes in young adults. There are more forms of diabetes than the commonly known type 1 and type 2. Dr Katherine Owen investigates the different characteristics of monogenic diabetes with the aim of creating systematic diagnostics for aetiology of diabetes, and implementing that in clinical care. The ultimate aim is to promote personalized medicine for everybody with diabetes.

Professor Stephen Gough talks about the development of personalised diabetes treatment. Prof. Stephen Gough believes that you cannot give every patient affected by diabetes the same treatment; where people react differently to treatments provides a background to his research. Prof. Gough aims to provide the right treatment to the right person at the right time in their disease for optimum results.

Professor Stephen Gough talks about the development of personalised diabetes treatment. An estimated 500 million people worldwide will be affected by diabetes within the next fifteen years. Professor Stephen Gough believes that you cannot give every patient affected by diabetes the same treatment, since people react differently to treatments. Professor Gough looks at the reasons behind differences in the way that people react to diabetes treatments, in order to improve care and reduce the health and economic costs associated with the disease. Professor Gough aims to provide the right treatment to the right person at the right time in their disease for optimum results.

Professor Stephen Gough talks about the development of personalised diabetes treatment. Prof. Stephen Gough believes that you cannot give every patient affected by diabetes the same treatment; where people react differently to treatments provides a background to his research. Prof. Gough aims to provide the right treatment to the right person at the right time in their disease for optimum results.